secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-09-14T20:05:41+00:00
Accession:  0001213900-26-099700
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio appoints Sanofi rare-disease GM and biopharma BD veteran to board
----------------------------------------------------------------------------

- Board appointed R. Duane Clark II (Sanofi rare-disease GM) and James Sapirstein (CEO of Cocrystal) as independent directors.
- Each director gets option for 100,000 shares (36-month vest) plus $50,000 annual cash retainer.
- Board enlarged to seven; both join Nominating and Corporate Governance Committee.
- Appointments target rare-disease commercialization for Ebstrocel and strategic partnering across pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/0001213900-26-099700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/ea0305404-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-099700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer